With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.
NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their...
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s shares closed yesterday at $95.03.Elevate Your Investing...
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced...